REGULATORY

Tap Consumption Tax Revenue to Ensure Stable Generic Supply: LDP League

By Takashi Ebisawa May 28, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A league of Liberal Democratic Party (LDP) lawmakers on generic medicines on May 27 submitted its proposal to the health minister calling for tapping an increase in consumption tax revenue to ensure the quality and stable supply of generics. The…

To read the full story

LDP Official: Higher Tax Revenue Could Fund Expansion of Minimum NHI Prices, Re-Pricing for Unprofitable Products
June 20, 2025
LDP Generic League Calls for Necessary Pricing Steps to Ensure Quality and Supply
May 22, 2025
LDP Lawmakers Urge Generic Industry to Ramp Up Production
February 28, 2025

REGULATORY

Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
Japan Identifies 28 New “Drug Loss” Products from 2021-23 Approvals
April 7, 2026
Japan OKs Zolgensma Intrathecal Form, Breyanzi Expansion, New EB Therapy
April 6, 2026
Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Challenges in a Post-AG Era: Ensuring a Reliable Supply System

By Tatsuya Otsuka

Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…